Esperion Therapeutics, Inc.
(NASDAQ : ESPR)

( )
ESPR After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.04%108.241.1%$605.41m
GILDGilead Sciences, Inc.
-2.93%74.340.9%$540.78m
AMGNAmgen Inc.
-1.39%174.921.1%$476.57m
REGNRegeneron Pharmaceuticals, Inc.
-0.92%383.122.7%$338.65m
BIIBBiogen Inc.
-2.17%323.551.2%$316.85m
ALXNAlexion Pharmaceuticals, Inc.
-0.40%113.091.9%$255.42m
BLUEBluebird Bio, Inc.
-0.30%184.3516.1%$198.90m
VRTXVertex Pharmaceuticals Incorporated
-1.57%142.531.9%$197.41m
ILMNIllumina, Inc.
-1.73%210.853.5%$160.91m
ALNYAlnylam Pharmaceuticals, Inc
-0.96%123.6610.0%$160.42m
NKTRNektar Therapeutics
-2.79%55.056.1%$153.38m
AAgilent Technologies, Inc.
-0.26%66.511.5%$152.00m
INCYIncyte Corporation
-2.17%95.972.5%$129.88m
BMRNBioMarin Pharmaceutical Inc.
-0.15%88.534.4%$100.67m
JUNOJuno Therapeutics, Inc.
-6.83%44.1713.5%$94.92m

Company Profile

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company focuses on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. It is in business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. Esperion Therapeutics was founded by Roger S. Newton and Charles L. Bisgaier on January 22, 2008 and is headquartered in Ann Arbor, MI.